18 MESES DE OS . SMALL CELL LUNG CÁNCER EN SEGUNDA LÍNEA . NUEVA ESPERANZA EN EL HORIZONTE PARA LOS PACIENTES . BRISTOL MYERS OBTIENE UNA SUPERVIVENCIA GENERAL ( OVERALL SURVIVAL - OS ) DE 18 MESES ... Con su ANTICUERPO GM1 Combinado Con OPDIVO ( NIVOLUMAB ) .

NEW HOPE ON THE HORIZON FOR PATIENTS WITH SCLC .

May 9, 2024 .

Ariel Lopez-Chavez, MD

Ariel Lopez-Chavez, MD, Medical Oncologist, Director Of Precision Medicine And Developmental Therapeutics at Allegheny Health Network Cancer Institute, Discusses Ongoing Research In The SMALL CELL LUNG CÁNCER ( SCLC ) Space .

Trials Are Currently Ongoing, Investigating Novel Agents For The Potential Treatment Of SCLC . Investigators On These Studies Aim To Address The High Unmet Needs In SCLC .

Lopez-Chavez Discusses Promising NEW Avenues For SCLC Treatment, Including With An Investigational GM1 ANTIBODY By Bristol Myers Squibb Which Showed Encouraging Results In COMBINATION With NIVOLUMAB ( OPDIVO ) in the SECOND-LINE Setting .

The Agent Achieved An 18-Month Median OVERALL SURVIVAL And Trials Are Ongoing For Its Use In Both Frontline And Combination With STANDAR CHEMOTHERAPY PLUS 

NIVOLUMAB .

Additionally, Lopez-Chavez Highlights The Potential of Radionuclide Therapy For Frontline SCLC And The Exploration Of Cellular Therapies, Which Are Similar To Those Being Investigated in the NON-SMALL CELL LUNG CÁNCER Space .

TRANSCRIPTIÓN : 0:09 | 

There Are Ones That Are Currently Going Towards Registration … And We Have Another GM1 ANTIBODY By [ Bristol Myers Squibb ] .

That One Looked Interesting In Their Initial Results In The Refractory Setting .

 In Particular, When They Combined That With NIVOLUMAB [ OPDIVO ] In The SECOND-LINE Setting, They Got a MEDIAN OVERALL SURVIVAL of Around 18 Months, Which Was Encouraging .

They Are Bringing it Into The Frontline Setting As Well .

They Are Also Studying It In Combination With CARBOPLATIN, ETOPÓSIDE, And NIVOLUMAB .The Results Were Not As Impressive As With The Latter, But It Is Something To Follow-Up On .

1:09 | We Also Have Radionuclide Therapy Also Coming Into The Frontline Setting … On More Space That I Am Interested In Is The Use Of Cellular Therapies . A Lot Of Companies Are Going In The Space Of Cellular Therapies, In Solid Tumors, In Particular In NON-SMALL CELL LUNG CÁNCER, And There Are Some Studies Now Going Into SMALL CELL LUNG CÁNCER . That Will Be Interesting To See What Therapies Are Capable Of .

BLOOMBERG : ¿ IAG Podría PAGAR DIVIDENDO A FINALES DE AÑO 2024 ? . The Owner Of BRITISH AIRWAYS Has Told Investors That Payouts Could Be Made Before The End Of the Year, Said The People , Asking Not To Be Identified Because The discussions Are Private .

 

GLAZMANN ( GRÍFOLS ) Da la Cara y Defiende en una Carta a los Accionistas la Actuación de la Compañía Ante el " Ataque " de Gotham . Grifols Prevé Cerrar en Junio la Venta del 20% de SHANGHAI RAAS ... ¿ COINCIDIENDO CON LA JUNTA DE ACCIONISTAS ... ?

Los Resultados de IAG Vuelan Más Alto Que los de Air France , KLM y Lufthansa . En la Junta de Accionistas se Pondrá Fecha al Retorno del Dividendo.

 

PharmaMar Rebota Desde los 27 euros ... Tan Solo Dos Cuestiones No Encajan ... Se Trata de Subidas en la Rectas Finales de Mercado y Sin Volumen ... y Sin Que se Despeine el Fondo Bajista Arrowstreet Capital, Limited Partnership .

 

IAG en el Primer Trimestre 2024 Ha Obtenido 540 Millones Más Versus Primer Trimestre 2023 . Un EBITDA de 68 Vs 9 . IAG Para Verano está Muy Bien Posicionada . XTB Da un Precio Objetivo de 2,50 euros .

 

Los Resultados están Por encima de las Previsiones del Mercado, Ya Que el Consenso de los Analistas Recogidos en Bloomberg Auguraba unas Pérdidas de 108 Millones de euros .

SN BIOSCIENCE RECEIVES FDA FAST TRACK DESIGNATION FOR SNB-101 FOR SMALL CELL LUNG CÁNCER ... Lo Que Sienta las Bases Para Poder Comercializarlo Inmediatamente Después de Completar los Ensayos Clínicos de FASE II . Por Recordar También Tiene el Status de ORPHAN DRUG .

 

PR NEWSWIRE .

SEOUL, South Korea , May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young -hwan) announced on May 7 that the FDA has Granted FAST TRACK Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a New Drug For Polymer Nanoparticle Anticancer under Clinical Trial . 

SNB-101 was designated as an ORPHAN DRUG for SMALL CELL LUNG CÁNCER and Pancreatic Cancer in July of last Year and February of This Year, Respectively . By Receiving FAST-TRACK designation this time, it is Evaluated That it Has laid the Groundwork That Can Be Commercialized Immediately After Completion of PHASE II CLINICAL TRIALS .

Despite a long period of REsearch and Development, SCLC still remains a field with high medical Unmet Needs . Currently, the FIRST-LINE STANDARD Treatment is a Combination Therapy of CISPLATIN And ETOPÓSIDE, a classic cytotoxic Anticancer Drug, and ' CLINICAL TRIALS ' are included as SECOND-LINE Treatments in the NCCN GUIDELINES .

FAST TRACK is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need . The FAST TRACK Designation facilitates the interactions with the FDA and allows a Rolling REVIEW For the Submission Package so it can be Reviewed in each section, rather than waiting until every section of the NDA is Completed . Additionally, it May Be Possible To Apply For ACCELERATED APPROVAL After The Completion of PHASE II CLINICAL TRIALS and PRIORITY REVIEW Immediately After The Completion of PHASE III  CLINICAL TRIALS When Qualified . ...